seekingalpha.com
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma, Inc.AYTUNASDAQ
LOADING
|||
Switch Symbol:
Latest News
Loading news...
zacks.com
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.
accessnewswire.com
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 second quarter.
zacks.com
New Strong Sell Stocks for February 2nd
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
accessnewswire.com
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m.
defenseworld.net
Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy
seekingalpha.com
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
accessnewswire.com
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.
accessnewswire.com
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit. The webcast will take place at 5:00 p.m.
accessnewswire.com
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.
defenseworld.net
Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Brokerages
Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) has been given a consensus recommendation of "Hold" by the five ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the
accessnewswire.com
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will be hosting an Investor Day on Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.
accessnewswire.com
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo DENVER, CO / ACCESS Newswire / December 15, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the commercial availability of EXXUA in the United States. EXXUA is the first and only 5HT1a agonist approved by the United States Food and Drug Administration for the treatment of major depressive disorder ("MDD"), representing a new way to treat MDD.
defenseworld.net
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU
AWM Investment Company Inc. purchased a new position in Aytu BioPharma Inc. (NASDAQ: AYTU) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 619,874 shares of the company's stock, valued at approximately $1,351,000. AWM Investment Company Inc. owned approximately 6.90%
accessnewswire.com
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL. Management will be presenting on Wednesday, December 3rd at 10:30 a.m.
seekingalpha.com
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript
Aytu BioPharma, Inc. ( AYTU ) Q1 2026 Earnings Call November 13, 2025 4:30 PM EST Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Greetings.
zacks.com
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
accessnewswire.com
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
Total net revenue of $13.9 million Net income of $2.0 million, or $0.21 net income per share basic Adjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments $32.6 million cash balance at September 30, 2025 Company remains on track to launch EXXUA ™ (gepirone) extended-release tablets ("EXXUA " ) in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / November 13, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 first quarter.
accessnewswire.com
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m.
accessnewswire.com
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2, 2030 under 35 U.S.C.